



Single-Cell Differential Network Analysis with Sparse Bayesian Factor Models

Michael Sekula¹, Jeremy Gaskins¹ and Susmita Datta²*

¹Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, United States, ²Department of Biostatistics, University of Florida, Gainesville, FL, United States

Differential network analysis plays an important role in learning how gene interactions change under different biological conditions, and the high resolution of single-cell RNA (scRNA-seq) sequencing provides new opportunities to explore these changing genegene interactions. Here, we present a sparse hierarchical Bayesian factor model to identify differences across network structures from different biological conditions in scRNA-seq data. Our methodology utilizes latent factors to impact gene expression values for each cell to help account for zero-inflation, increased cell-to-cell variability, and overdispersion that are unique characteristics of scRNA-seq data. Condition-dependent parameters determine which latent factors are activated in a gene, which allows for not only the calculation of gene-gene co-expression within each group but also the calculation of the co-expression differential gene-gene associations across groups by analyzing simulated datasets and a SARS-CoV-2 case study dataset.

OPEN ACCESS

Edited by:

Saurav Mallik, Harvard University, United States

Reviewed by:

Aimin Li, Xi'an University of Technology, China Soumita Seth, Aliah University, India

> *Correspondence: Susmita Datta susmita.datta@ufl.edu

Specialty section:

This article was submitted to Computational Genomics, a section of the journal Frontiers in Genetics

Received: 07 November 2021 Accepted: 21 December 2021 Published: 04 February 2022

Citation:

Sekula M, Gaskins J and Datta S (2022) Single-Cell Differential Network Analysis with Sparse Bayesian Factor Models. Front. Genet. 12:810816. doi: 10.3389/fgene.2021.810816 Keywords: Bayesian, factor model, scRNA-seq, gene co-expression network, differential network analysis

1 INTRODUCTION

Gene network modeling has become essential to the understanding of complex biological systems related to health and disease. These networks allow researchers to uncover and interpret relationships and interactions between genes during different biological processes (Blencowe et al., 2019). There are several popular methods for constructing gene networks from microarray and bulk RNA sequencing data (Margolin et al., 2006; Langfelder and Horvath, 2008; Huynh-Thu et al., 2010), and more recently, methods for identifying gene networks from single-cell RNA sequencing (scRNA-seq) data have also been proposed (Specht and Li, 2016; Chan et al., 2017; Matsumoto et al., 2017; Sekula et al., 2020). Interestingly, the vast majority of these methods have focused only on analyzing gene expressions from one cellular population, such as a single tissue type, disease, or environmental condition.

Since biological systems are highly dynamic, there is also great interest in performing differential network analysis to examine the changes in network structure under different biological settings. In the context of bulk population data (i.e., microarray and bulk RNA sequencing), efforts have been made to develop different strategies for identifying differences between gene-gene networks. Some approaches propose qualitative analyses through visual inspection of different network topologies (Caldana et al., 2011; Weston et al., 2011), while others rely on statistical tests to determine differences across conditions (Choi and Kendziorski, 2009; Gill et al., 2010; Fukushima, 2013).

1

For scRNA-seq data, some research has been focused on providing guidelines and procedures for differential network analysis based on existing methods that have been developed to analyze different types of transcriptome data (e.g., bulk RNA sequencing, microarray). Cui et al. (2021) propose a pipeline for comparing two single-cell clusters that includes differential gene correlation analysis from McKenzie et al. (2016), weighted correlation network analysis from Langfelder and Horvath (2008), and differential network analysis with the method DiffCoEx (Tesson et al., 2010). Wang et al. (2017) present several proof-of-concept analyses of scRNA-seq data to identify genes that are differentially connected across distinct biological conditions by utilizing a differential connectivity test originally developed by Gill et al. (2010) for microarray gene expression data.

Some research has also been focused in developing new methods designed specifically for scRNA-seq data to identify and compare gene networks from two (or more) biological conditions. In Chiu et al. (2018), a differential network analysis method for scRNA-seq data is proposed that first determines a sample size corrected gene-gene correlation matrix for each cellular state and then identifies differential gene-gene pairs across the states. Ye et al. (2020) use coexpression network analysis and subgraph learning to identify interactive gene groups within subpopulations of cells from scRNA-seq data. Both Dai et al. (2019) and Li et al. (2021) propose novel methods to create cell-specific networks to examine the overall associations between genes for each individual cell. From these cell-specific networks, researchers can further identify changes in gene-gene networks across different cellular populations and/or different time points.

In this work, we propose a hierarchical Bayesian factor model for constructing gene co-expression networks (GCNs) from scRNA-seq data to explore differences in the network structure across various cell groups due to different biological conditions, cell types, cell stages, or other group choice. Treatment-dependent parameters in our model determine which latent factors are activated in a gene, thereby allowing for the calculation of gene-gene co-expression within each treatment group. For simplicity, we consider a two-group setting and refer to these groups as treatment and control, but our model can easily be extended to a multiple group scenario, if necessary.

The rest of this manuscript is organized as follows. We define our proposed model and inference for differential network analysis in **Section 2**. Results from simulation studies and real data analysis are presented in **Section 3** to demonstrate the performance of our methodology. In **Sections 4 and 5**, we conclude with a discussion on our results and findings.

2 METHODS

2.1 Hierarchical Bayesian Factor Model for Two Treatment Groups

Let Y_{gi} be the expression count of gene g (g = 1, ..., G) in cell i (i = 1, ..., N) for treatment $t_i \in \{0, 1\}$, where $t_i = 0$ represents that cell i

belongs in the control (reference) group and $t_i = 1$ for the treatment group. We assume that each expression comes from the Poisson(μ_{gi}) distribution (conditionally) and model the logmean $log(\mu_{gi})$ through the representation

$$log(\mu_{gi}) = \beta_g + t_i \delta_g + \sum_{f=1}^F \lambda_{if} \alpha_{gf;t_i} - \left\{ \sum_{f=1}^F \frac{\alpha_{gf;t_i}^2}{2} \right\}.$$
(1)

For each cell *i*, there are *F* associated latent factors $\lambda_i = \{\lambda_{i1}, \ldots, \lambda_{iF}\}$ that impact the expression. Each factor can be thought of as some unique cellular attribute (e.g., cell stage, pseudotime point) that will only affect a specific set of related gene expressions. Since we are defining our model on the log scale, we assume these factors come from a Normal(0, 1) distribution. Marginally over λ_i , the parameter β_g denotes the log-mean expression for gene *g* in the control group, and $\beta_g + \delta_g$ is the log-mean expression for gene *g* in the treatment group. Hence, δ_g represents the log-fold change in the expression for gene *g*.

The magnitude of the impact of factor f on gene g in treatment t is influenced by the parameter $\alpha_{gf;t} \in \mathbb{R}$. With this setup, the expression for gene g in treatment t is minimally impacted by factors with $\alpha_{gf;t}$ values close to 0 and greatly impacted by factors with absolute values of $\alpha_{gf;t}$ much greater than 0. It is important to note that the $\alpha_{gf;t}$'s are treatment-dependent which allows factors to impact the gene expressions differently across the treatments. Clearly, if $\alpha_{gf;0}$ and $\alpha_{gf;1}$ have similar values, then factor f has a similar influence on the gene expression in both treatments. However, the more interesting case is when $\alpha_{gf;0}$ and $\alpha_{gf;1}$ have very different values, which indicates a difference in the impact of factor f on gene g between the groups. By examining the differences between the $\alpha_t = {\alpha_{gf;t}} {}_{(g,f)}$ matrices, we can identify differences between the gene networks of the treatment groups.

For most factors, we assume that the values of $\alpha_{gf:0}$ and $\alpha_{gf:1}$ in our model will be similar. That is, we expect $\alpha_{gf:0}$ and $\alpha_{gf:1}$ to be similar for most (g, f) pairs. We also expect each factor f to impact only a small number of genes, and so the α_t matrices will be sparse. To that end, we define the following hierarchy on the $\alpha_{gf:t}$ parameters:

$$\begin{aligned} &\alpha_{gf;t} \sim Normal(\tilde{\alpha}_{gf}, \kappa_{gf;t}^2 \tau_f^2), \\ &\kappa_{gf;t} \sim half - Cauchy(0, 1), \\ &\tau_f \sim half - Cauchy(0, 1), \end{aligned}$$
(2)

$$\begin{aligned} \tilde{\alpha}_{gf} &\sim Normal(0,\zeta^2), \\ \zeta &\sim half - Cauchy(0,1), \end{aligned}$$
 (3)

where *half–Cauchy*(0, 1) is the standard half-Cauchy distribution with the probability density function

$$p(x) = \frac{2}{\pi(1+x^2)}, x > 0.$$

We refer to this model definition as Sparse Factor Model -Single HorseShoe (SFM-SHS). Under this scheme, the horseshoe prior (Carvalho et al., 2009) placed on each $\alpha_{gf,t}$ in **Eq. 2** will help shrink the values of $\alpha_{gf,0}$ and $\alpha_{gf,1}$ together toward the common value $\tilde{\alpha}_{gf}$. For a given factor *f*, we define τ_f as the global shrinkage parameter and the $\kappa_{gf,t}$'s as the local shrinkage parameters. The global shrinkage parameter will pull the values of $\alpha_{gf;0}$ and $\alpha_{gf;1}$ toward $\tilde{\alpha}_{gf}$ across g = 1, ..., G, while the treatment-dependent local shrinkage parameters will allow some values to be much different than $\tilde{\alpha}_{gf}$. Thus, the $\kappa_{gf;t}$'s can account for any variability between the groups. Our model favors borrowing information across treatments, so it should be efficient for factor-gene effects that are common. Nevertheless, the horseshoe priors allow big differences to accommodate differences between treatments.

To achieve more sparsity, a horseshoe prior could also be placed on the $\tilde{\alpha}_{gf}$ parameters to help shrink most of these values close to 0. To that end, we may replace **Eq. 3** in our model with the following:

$$\begin{aligned} \tilde{\alpha}_{gf} &\sim Normal(0, \omega_{gf}^2 \zeta^2), \\ \omega_{gf} &\sim half - Cauchy(0, 1), \\ \zeta &\sim half - Cauchy(0, 1). \end{aligned}$$

$$(4)$$

We refer to this second model definition as Sparse Factor Model - Double HorseShoe (SFM-DHS). Here, ζ is a global shrinkage parameter that will pull the values of $\tilde{\alpha}_{gf}$ toward 0. In **Eq. 4**, we introduce local shrinkage parameters (ω_{gf} 's) to allow some of the $\tilde{\alpha}_{gf}$ values to be much different than 0. Therefore, the horseshoe priors on the $\alpha_{gf,t}$ parameters (**Eq. 2**) will promote sparsity in the treatment difference and the horseshoe priors on the $\tilde{\alpha}_{gf}$ parameters (**Eq. 4**) will promote sparsity in the underlying common network.

The flexibility of our defined factor structure allows for the zero-inflation and high cell-to-cell variability typical of scRNAseq data. For a given factor *f*, the latent λ_{if} is unique to each cell *i* and only affects a particular gene within a treatment when $\alpha_{gf,t} \neq$ 0. If the activated factors $\lambda_{if}\alpha_{gf;t}$ for a given gene are highly negative, then μ_{gi} will be very small and account for the high proportion of zeros typical of this data. Conversely, large positive values of the factors will increase μ_{gi} (relative to the baseline of either $exp\{\beta_g\}$ for the control group or $exp\{\beta_g + \delta_g\}$ for the treatment group) and yield extremely large counts, i.e., overdispersion. In Eq. 1, the adjustment term of $-\left\{\sum_{f=1}^{F} \frac{\alpha_{gf:t_i}^2}{2}\right\}$ is included in our model to ensure that $E[Y_{gi}]$ in the control group is equal to $exp\{\beta_g\}$ and $E[Y_{gi}]$ is equal to $exp\{\beta_g\}$ + δ_g for the treatment group (after marginalizing out λ_i) regardless of the $\alpha_{ef:t}$ values. While we choose to let Y_{ei} follow a Poisson distribution conditional on the λ_i terms, the variance of Y_{gi} (marginal on λ_i) is

$$Var[Y_{gi}] = exp\{\beta_g + t_i\delta_g\} \begin{bmatrix} 1 + exp\{\beta_g + t_i\delta_g\} \prod_{f=1}^{F} (exp\{\alpha_{gf;t}^2\} - 1) \end{bmatrix},$$
$$Var[Y_{gi}] > exp\{\beta_g + t_i\delta_g\}[1] = E[Y_{gi}].$$
(5)

Hence, Y_{gi} is conditionally Poisson but marginally overdispersed.

To complete the specification of our Bayesian model, we define priors for the average gene expression parameters as $\beta_g \sim Normal(0, \sigma_{\beta}^2)$ and $\delta_g \sim Normal(0, \sigma_{\delta}^2)$, with standard deviation hyperparameters σ_{β} and σ_{δ} from half-Cauchy(0, 1). Our methodology does rely on the tuning parameter F, a fixed number of latent factors that is often unknown. Nevertheless, one can fit multiple models with different numbers of factors and choose the most suitable model based on comparing the estimated number of differential edges between the different choices of F. As discussed in more detail later in **Section 3.1**, we found that the overall results will remain relatively consistent for different choices of the tuning parameter F.

2.2 Network Structure

This model uses the parameters $\alpha_{gf;t}$ to characterize the relationship between the genes and a set of latent factors; however, our real interest is in using these parameters to learn about the genes themselves (marginally over these factors). While the α_t matrices in our model impose a crude network structure on the gene expressions for each treatment, the individual $\alpha_{gf;t}$ parameters are non-identifiable, and so we cannot perform inference about these parameters directly. To that end, we consider the matrices $A_t = \alpha_t \alpha_t^T$ whose elements are identifiable.

For a given treatment *t*, the (g, g') element $(g \neq g')$ of the $G \times G$ matrix A_t provides a summation of impact by the associated factors that are active in both genes *g* and *g'* since $A_{t(g,g')} = \sum_{f=1}^{F} \alpha_{gf;t} \alpha_{g'f;t}$. This expression also happens to be equal to the covariance (after marginalizing out λ_i) between the values of $log(\mu_{gi})$ and $log(\mu_{g'i})$ in treatment *t*,

$$Cov\left[log(\mu_{gi}), log(\mu_{g'i})\right] = \sum_{f=1}^{F} \alpha_{gf;t} \alpha_{g'f;t}.$$

With the marginal variance for $log(\mu_{gi})$ being

$$Var[log(\mu_{gi})] = \sum_{f=1}^{F} \alpha_{gf;t}^{2},$$

the correlation between $log(\mu_{gi})$ and $log(\mu_{g'i})$ is defined as

$$Corr[log(\mu_{gi}), log(\mu_{g'i})] = \rho_{gg';t} = \frac{\sum_{f=1}^{F} \alpha_{gf;t} \alpha_{g'f;t}}{\sqrt{\left(\sum_{f=1}^{F} \alpha_{gf;t}^{2}\right) \left(\sum_{f=1}^{F} \alpha_{g'f;t}^{2}\right)}},$$
(6)

We focus our interest on the marginal correlation of the logmeans due to the simplistic nature of the correlation structure and its reliance on only the α_{gfit} parameters. As displayed in **Eq. 5**, the variance expression of Y_{gi} includes a set of β_g and δ_g parameters that cannot be factored out, which means the correlation structure between Y_{gi} and $Y_{g'i}$ will depend on the average expression for each gene in each treatment. For this reason, we do not utilize the correlation structure between Y_{gi} and $Y_{g'i}$.

2.3 Network Inference

Our methodology is coded in Stan (Stan Development Team, 2020), and the usual approach to Bayesian inference in Stan is to generate samples from the posterior distributions with Hamiltonian Monte Carlo (HMC; Neal, 2011). The estimated gene-gene network structure $\tilde{N}_t = \{\tilde{n}_{gg',t}\}_{(g,g')}$ within each treatment group is obtained by analyzing the posterior of the

marginal correlation matrix in **Eq. 6**. To provide a quantifiable value of the association between genes g and g' within treatment t, M samples of each (g, g') element in the correlation matrix are used to calculate the posterior mean $\hat{\rho}_{gg';t} = \frac{1}{M} \sum_{m=1}^{M} \rho_{gg';t}^{(m)}$. Additionally, the credible interval (CrI) of the posterior is examined to determine whether or not genes g and g' are associated with one another within each treatment group, separately. For a given level of significance α^* , two genes will have a significant association when zero is excluded from the 100(1 - α^*)% CrI. To rank correlations by significance within each treatment group, the smallest a^* such that the 100(1 - a^*)% CrI includes 0 for the given gene-gene pair can be determined. The corresponding a^* value indicates the proportion of the posterior distribution outside of the smallest CrI that includes 0, which can be viewed as an approximate "*p*-value".

When performing differential network analysis, the interest is in examining the difference between $\rho_{gg';0}$ and $\rho_{gg';0} - (\theta_{gg'} = \rho_{gg';0} - \rho_{gg';1})$, and both the posterior mean $\hat{\theta}_{gg'} = \frac{1}{M} \sum_{m=1}^{M} (\rho_{gg';0}^{(m)} - \rho_{gg';1}^{(m)})$ and the 100(1 – α^*)% CrI for each gene-gene pair correlation difference are obtained from the posterior. If zero is excluded from the 100(1 – α^*)% CrI, the difference between the treatment correlations for gene g and gene g' is significant. An approximate "p-value" can also be determined and used to rank the differences in correlation between the treatment groups.

We note that an iterative Markov Chain Monte Carlo (MCMC) approach may be computationally intensive for larger scRNA-seq datasets and will require the user to perform various diagnostic checks to ensure MCMC convergence and mixing (Cowles and Carlin, 1996). For those reasons, we present an alternative strategy for inference of our model parameters. A posterior mode estimate from our model can be obtained by maximizing the joint posterior via the *optimizing* function from Stan. With this optimized estimate, we calculate the marginal correlation structure from each treatment group defined in **Eq. 6** and determine each gene-gene pair correlation difference $\hat{\theta}_{gg'} = \hat{\rho}_{gg';0} - \hat{\rho}_{gg';1}$. The $\hat{\theta}_{gg'}$ values can be ranked based on their magnitudes to determine the gene-gene pairs whose correlations are most different at the posterior mode, but the significance of each difference cannot be directly determined from a single optimization.

To produce an estimate of variability for $\theta_{gg'}$, we utilize a nonparametric bootstrap procedure. For each bootstrap iteration (m_b) we perform the following:

- Resample the cellular data with replacement within each treatment group. Here, the number of cells within each treatment group remains the same, but a new sample of cellular data for each treatment group is randomly selected from the original treatment group data.
- 2) Obtain a posterior mode estimate from the resampled data with the *optimizing* function from Stan.
- Determine the marginal correlation structure as defined in Eq.
 6 for each treatment and then calculate θ^{mb}_{gg'} = ρ^{mb}_{gg';0} ρ^{mb}_{gg';1}.

From the M_b total bootstrap samples, a $100(1 - \alpha^*)\%$ confidence interval (CI) can be created and analyzed for $\rho_{gg';0}$, $\rho_{gg';1}$, and $\theta_{gg'}$ in the same manner as previously described above



for the posterior CrIs. **Figure 1** displays a flowchart of our proposed methodology. We note that we describe three estimation approaches/algorithms for our methodology, each with varying levels of computational complexity. The nonparametric bootstrap procedure is our preferred approach as will be shown in **Section 3**.

3 RESULTS

3.1 Simulation Studies

To evaluate the performance of our methodology, we simulated count data from marginal zero-inflated negative binomial distributions via the NORmal To Anything (NORTA) algorithm (Cario and Nelson, 1997). The NORTA algorithm generates a random vector from a multivariate standard normal distribution with a given correlation structure and transforms it into a random vector with a specified marginal distribution. Counts were generated with the *rnorta* function from the R package SimCorMultRes (Touloumis, 2016), and the ZIM package (Yang et al., 2018) was used to estimate the

TABLE 1 Comparison of the "true" differences between networks and the estimated differences between networks in the simulation studies for each differential network method. Results displayed for SFM-SHS and SFM-DHS are from the bootstrap estimation procedure. In Sim 1–3, there are 325 "true" differential edges and in Sim 4 there are 1, 300 "true" differential edges.

Sim 1: G = 50, N = 1, 000				
Network Structure A	TPR	FDR	AUROC	Diff. Edges
SFM-SHS; <i>F</i> = 8	0.782	0.000	0.980	254
SFM-DHS; <i>F</i> = 10	0.809	0.123	0.966	300
DGCA	0.825	0.056	0.935	284
scdNet	0.908	0.187	0.956	363
Network Structure B				
SFM-SHS; <i>F</i> = 7	0.855	0.007	0.992	280
SFM-DHS; <i>F</i> = 13	0.825	0.118	0.963	304
DGCA	0.858	0.021	0.983	285
scdNet	0.680	0.208	0.861	279
Sim 2: G = 50, N = 500				
Network Structure A	TPR	FDR	AUROC	Diff. Edges
SFM-SHS; <i>F</i> = 7	0.732	0.040	0.942	248
SFM-DHS; <i>F</i> = 8	0.840	0.099	0.946	303
DGCA	0.892	0.020	0.955	296
scdNet	0.908	0.117	0.966	334
Network Structure B				
SFM-SHS; <i>F</i> = 7	0.874	0.004	0.979	285
SFM-DHS; <i>F</i> = 12	0.855	0.045	0.963	291
DGCA	0.849	0.028	0.942	284
scdNet	0.628	0.143	0.872	238
Sim 3: G = 50, N = 2, 000				
Network Structure A	TPR	FDR	AUROC	Diff. Edges
SFM-SHS; <i>F</i> = 8	0.871	0.000	0.997	283
SFM-DHS; <i>F</i> = 8	0.985	0.140	0.983	372
DGCA	0.945	0.130	0.978	353
scdNet	0.972	0.296	0.983	449
Network Structure B				
SFM-SHS; <i>F</i> = 7	0.898	0.000	0.999	292
SFM-DHS; <i>F</i> = 8	0.985	0.075	0.998	346
DGCA	0.957	0.116	0.986	352
scdNet	0.954	0.213	0.981	394
Sim 4: G = 100, N = 1, 000				
Network Structure A	TPR	FDR	AUROC	Diff. Edges
SFM-SHS; <i>F</i> = 8	0.922	0.000	0.997	1,199
SFM-DHS; <i>F</i> = 8	0.958	0.162	0.970	1,487
DGCA	0.875	0.023	0.972	1,165
scdNet	0.941	0.184	0.976	1,498
Network Structure B				
SEM-SHS: F = 7	0.004	0.025	0 994	1 285
on m on o, r = r	0.964	0.020	0.001	1,200
SFM-DHS; <i>F</i> = 10	0.964 0.850	0.137	0.974	1,280
SFM-DHS; <i>F</i> = 10 DGCA	0.964 0.850 0.883	0.023 0.137 0.042	0.974 0.970	1,280 1,199

parameters of the zero-inflated negative binomial distributions from genes randomly selected from the genes considered in a previous analysis (Sekula et al., 2020) of the mouse microglia cell data from Tay et al. (2018). It is important to emphasize that the simulated data come from a different generating model than our proposed estimation approach.

We considered four different simulation schemes to create datasets of different sizes, using either G = 50 or G = 100 genes and setting the total number of cells to either N = 500, N = 1,000, or N = 2,000 (see **Table 1** for details of each simulation scheme).

To define treatment groups, the cells were divided equally into the control group (t = 0) and the treatment group (t = 1). Correlation structures for each treatment network were fixed to create a differential structure of 325 different edges with G = 50 genes (Sim 1, Sim 2, and Sim 3) and 1,300 different edges with G = 100 genes (Sim 4).

In our simulation data, we control the correlation structures by sorting genes into ten equal groups (e.g., Group 1 consisted of the first set of *G*/10 genes, Group 2 consisted of the second set of *G*/10 genes). Genes within the same group are defined to be highly correlated and share correlation structures across the other gene groups. Two different sets of correlation structures (Network Structure A and Network Structure B) were utilized for each simulation scheme, and the magnitudes of the "true" differences between correlations ($\theta_{gg'} = \rho_{gg';0} - \rho_{gg';1}$) ranged from 0.27 to 1.43 as displayed in **Figure 2**. For Network Structure B, some of the gene-gene pairs were simulated to have opposite correlation directions in each treatment group, thereby creating larger correlation differences between the groups.

Two versions of our sparse Bayesian factor methodology were investigated in the simulation studies. In our first model version SFM-SHS, the priors defined in **Eqs. 2**, **3** are placed on the $\alpha_{gf,t}$ and $\tilde{\alpha}_{gf}$ parameters, respectively (i.e., we use horseshoe priors on the $\alpha_{gf,t}$'s but not on the $\tilde{\alpha}_{gf}$'s). Recall that this encourages similarity between α_0 and α_1 , but does not encourage sparsity in the shared base network $\tilde{\alpha}$. For the second model version SFM-DHS, the prior on each $\tilde{\alpha}_{gf}$ parameter in **Eq. 3** is replaced with the horseshoe prior defined in **Eq. 4**.

Using the simulated data, we ran our proposed models in R (R Core Team, 2018) interfacing with Stan through the package rstan (Stan Development Team, 2020). Here, we utilize the bootstrap procedure for parameter estimation and inference was performed on 1,000 bootstrap samples. To investigate whether the number of factors (F) makes any impact on model performance, we ran both models multiple times and input a different number of factors for each run, starting with F =5 and increasing the number of factors up until F = 20. From our simulation studies, we found that area under the receiver operating characteristic curve (AUROC) for the performance of our models is relatively consistent with choices of F that are greater than 5, see Table 2. The inverse of the approximate "*p*-value" (defined in Section 2.3) for each $\hat{\theta}_{gg'}$ was used for the AUROC calculations of SFM-SHS and SFM-DHS. When determining true positive rate (TPR) and false discovery rate (FDR) for our methods, we utilized the 95% CIs of the difference between each $\rho_{gg';0}$ and $\rho_{gg';1}$ pair for each dataset ($\theta_{gg'}$).

To identify an appropriate choice for the tuning parameter F, the number of factors in our model, we examined the number of significant differential network edges. In **Figure 3**, we plotted the proportion of differential network edges (number of differential network edges divided by $\frac{G(G-1)}{2}$) determined by both SFM-SHS and SFM-DHS using different choices of F. From this figure, we see that the proportion of differential edges tends to increase (as F increases) up to a peak and then flattens out or decreases for larger values of F. Based on these observations, we determined the "best" model choice for each of our models by identifying the "peak" in the proportion of differential network edges plot after



treatment).

TABLE 2 Example comparisons of AUROC and number of significant differential edges (Diff. Edges) from Sim 1 when different choices of *F* are input into the SFM-SHS and SFM-DHS methods. Results are presented from the bootstrap estimation procedure.

SFS-SHS	Sim 1: G = 50, N = 1, 000					
	Network	structure A	Network structure B			
	AUROC	Diff. Edges	AUROC	Diff. Edges		
F = 5	0.886	217	0.888	278		
F = 7	0.996	228	0.992	280		
F = 8	0.980	254	0.984	260		
F = 10	0.983	228	0.983	266		
F = 12	0.981	222	0.979	256		
F = 13	0.979	215	0.982	253		
F = 15	0.980	224	0.973	253		
F = 18	0.974	212	0.979	255		
F = 20	0.973	197	0.981	232		
	Network	structure A	Network structure B			
SFS-DHS	AUROC	Diff. Edges	AUROC	Diff. Edges		
F = 5	0.882	210	0.892	287		
F = 7	0.990	242	0.982	292		
F = 8	0.969	280	0.976	292		
F = 10	0.966	300	0.974	283		
F = 12	0.960	300	0.973	298		
F = 13	0.946	288	0.963	304		
F = 15	0.955	292	0.956	296		
F = 18	0.952	272	0.960	280		
F = 20	0.951	282	0.960	279		

The number in bold font denotes the "peak" of the differential edges across the different number of factor choices for each network structure.

F = 5 factors. We focus on the results of the "best" model choice of both SFM-SHS and SFM-DHS for the remainder of this manuscript.

For the simulation studies, we ran also analyses with two other differential network methods that detect differences based on correlation structures between groups. One of the competitor methods we considered was Differential Gene Correlation Analysis (DGCA; McKenzie et al., 2016), which is an R package developed for identifying differential correlations between gene pairs in various types of genomic data (microarray, bulk RNA-seq, scRNA-seq, etc.). DGCA transforms correlation coefficients to z-scores and uses differences in z-scores to generate empirical *p*-values for the differential correlation between genes. These empirical *p*-values are then used to calculate q-values for an FDR threshold, and a q-value of 0.05 was set to denote significant differences for this method.

The other method considered in our simulated studies was scRNA-seq-based differential network analysis (scdNet), which is a differential network method developed specifically for scRNA-seq data by Chiu et al. (2018). In scdNet, a sample size adjustment transformation is first applied to the correlation coefficients within each cellular group and then statistical inference is performed on the differences in the transformed correlations across groups. The scdNet method provides *p*-values to represent differential results for each gene-gene pair, and we controlled the FDR with the Benjamini and Hochberg (1995) procedure. A

threshold of 5% was used to indicate significant differences with scdNet.

For each simulated dataset, we compared the significant differences between networks that were identified by each method (SFM-SHS, SFM-DHS, DGCA, and scdNet) to the "true" differences between networks. The measures of TPR, FDR, AUROC, and the number of edges that were classified as significantly different between networks by each method are displayed in Table 1. From this table, we see that our differential network methodology performs quite well compared to the competitor methods of DGCA and scdNet. Both SFM-SHS and SFM-DHS have high TPRs and AUROCs while also controlling the FDRs to a nominal rate. In general, SFM-SHS tends to be a bit more conservative and detects fewer significant edges than SFM-DHS, but SFM-SHS performs better at controlling FDRs below a threshold of 5%. In fact, SFM-SHS was the only method out of the four to consistently control the FDR to a nominal rate across the simulation cases, while scdNet tends to have the highest FDR. The AUROCs for both SFM-SHS and SFM-DHS are also comparable or better than the AUROCs by DGCA and scdNet across most simulations.

To demonstrate the utility of bootstrap estimation compared to the other parameter estimation techniques discussed in Section 2.3, we performed a secondary analysis comparing the results of our methods from bootstrapping to the results of our methods generated by a single optimization and by a full HMC sampler. For the single optimization technique (i.e., finding the posterior mode), the significance of each difference cannot be directly determined; therefore, we identified the Top 10% of edges with the largest difference between treatment groups and calculated the AUROC with the magnitudes (absolute values) of the estimated correlation differences. For the full HMC, we utilized rstan and combined results from 4 separate chains, with each chain running 1,000 warmup iterations and 1,000 sampling iterations for a total of 4,000 samples. Due to the slow speed of HMC sampling, only the results from the smallest simulated datasets (Sim 2: G = 50 genes and N = 500 cells) are presented.

The results in **Table 3** highlight the benefits of using optimization and bootstrapping. Both the full HMC sampler and the bootstrap technique obtain high TPRs and AUROCs, but the HMC sampler tends to have higher FDRs and also has very long computational times. The single optimization technique is also able to achieve high AUROC simply by ranking the magnitudes of the correlation differences between groups. Thus, a single optimization could be useful as a method to quickly identify highly differential edges between networks. We note that bootstrap optimizations can be run simultaneously in parallel and by increasing the number of available cores, the computational efficiency of the bootstrap technique will be increased.

3.2 Case Study

To further examine our proposed methodology, we analyzed the real dataset from Bacher et al. (2020), which consists of scRNAseq expressions derived from SARS-CoV-2-reactive memory T cells. This data was obtained from the Gene Expression Omnibus (GEO) database under accession number



GSE162086. We examined 1,833 cells that were identified by Bacher et al. (2020) as cells with distinct transcriptional profiles related to cytotoxic-Th1 and cycling. These cells are divided into two patient groups: $N_0 = 462$ cells are from non-hospitalized patients with SARS-CoV-2 and the remaining $N_1 = 1$, 371 cells come from patients hospitalized with SARS-CoV-2. After filtering out genes that were not expressed in at least 20% of the cells, we used the R package MAST (Finak et al., 2015) to identify G = 130 differentially expressed genes with a log2 fold change (as estimated by MAST) of at least $\log_2(1.2)$ for further analysis.

For each method considered in **Section 3.1**, we conducted a differential network analysis and ranked each gene by the number of significant differential connections. SFM-SHS and SFM-DHS were implemented with the bootstrapping estimation approach, and we selected the "best" model choice by identifying the "peak" in the number of differential edges starting with F = 5 factors and increasing the number of factors up to F = 20. The UpSet plot (Lex et al., 2014) for the intersection between the differential edges detected by each method is displayed in **Figure 4**. The dark circles in each column of the UpSet plot indicate the

methods associated with the intersection and the bar above each column represents the number of differential edges in the intersection.

From **Figure 4**, we see that the methods performed quite differently as only 388 edges were common across all four methods. SFM-SHS was the most conservative method and detected 608 differential edges, while scdNet method detected 6,690 differential edges, which is nearly 80% of the 8,385 total number of possible edges. Because the differential network analyses from the methods were so different, we selected the top genes with the most gene-gene pair connections from each method and used those top differentially connected genes (DCGs) to evaluate the performance of the methods in this case study analysis. A total of 14 DCGs (approximately 10% of the *G* = 130 total genes) were identified from each of the SFM-SHS, SFM-DHS, and DGCA analyses. From the scdNet analysis, 15 DCGs were chosen because three genes tied for the 13th, 14th, and 15th ranks.

In **Figure 5**, the UpSet plot for the intersection between the top DCGs detected by each differential network method is displayed. Here, the bar above each column in the figure represents the

TABLE 3 | Results for SFM-SHS and SFM-DHS when utilizing bootstrap (Boot), HMC, and the Top 10% of differential edges from a single optimization. Times for Boot represent the average time of one posterior optimization of a single resampled dataset; similarly, HMC time is the average time for a single MCMC chain.

Sim	2:	G	=	50.	N	=	500
•••••	_	-		,	•••		

Network Structure A	TPR	FDR	AUROC	Diff. Edges	Time
SFM-SHS; Boot, $F = 7$	0.732	0.040	0.942	248	5.6 s
SFM-SHS; HMC, $F = 7$	0.908	0.366	0.912	465	3.2 days
SFM-SHS; Top 10%, F = 7	0.354	0.065	0.803	123 ^a	4.9 s
SFM-DHS; Boot, F = 8	0.840	0.099	0.946	303	75.6 s
SFM-DHS; HMC, $F = 8$	0.840	0.000	0.984	273	4.6 days
SFM-DHS; Top 10%, F = 8	0.369	0.024	0.910	123 ^a	18.0 s
Network Structure B					
SFM-SHS; Boot, $F = 7$	0.874	0.004	0.979	285	8.0 min
SFM-SHS; HMC, $F = 7$	0.975	0.076	0.985	343	2.7 days
SFM-SHS; Top 10%, F = 7	0.366	0.033	0.928	123 ^a	16.8 min
SFM-DHS; Boot, $F = 12$	0.855	0.045	0.963	291	11.0 min
SFM-DHS; HMC, $F = 12$	0.849	0.148	0.922	324	5.1 days
SFM-DHS; Top 10%, F = 12	0.375	0.008	0.933	123 ^a	17.8 min

^aNumber of edges are fixed.



number of DCGs in the intersection. Interestingly, there was not much overlap in the top DCGs detected by the methods considered in this analysis. Our methods (SFM-SHS, SFM-DHS) detect seven unique DCGs from the other methods, whereas DGCA and scdNet identified six and nine unique DCGs, respectively.

Only three genes (*RPS26*, *RGCC*, *RPL3*) were common among the top DCGs selected by each method. These three genes play an important role in any immune-related disorders. *RPS26* and

RPL3 are ribosomal proteins (RP) and both are related to influenza viral RNA transcription and replication. RPs are needed for protein biosynthesis of viruses controlling replication, regulation, and infection inside the host cells. However, a small percentage of these proteins trigger the immune pathway against viruses and protect the host cells. Hence, RPs are now being considered for potential therapeutics for SARS-CoV-2 or any such viral infections (Rofeal and El-Malek, 2020).



To evaluate the biological relevancy of the top DCGs from each method, clusters of gene ontology (GO) categories were created with the functional annotation clustering tool from the database for Annotation, Visualization, and Integrated Discovery (DAVID; Huang et al., 2009a; Huang et al., 2009b). An enrichment score is calculated by DAVID for each cluster to help identify clusters that are involved in more enriched (important) biological roles. As it has been suggested that more attention should be given to groups with enrichment scores greater of 1.3 or higher (Huang et al., 2009b), we used a score threshold of 1.3 to classify clusters as enriched.

SFM-SHS had two enriched clusters from the DAVID functional annotation clustering analysis, while the three other methods (SFM-DHS, DGCA, and scdNet) had just one enriched cluster. SFM-DHS had the cluster with the highest Enrichment Score (3.46), and the top GO terms associated this cluster include SRP-dependent cotranslational protein targeting to membrane, viral transcription, and nuclear-transcribed mRNA catabolic process, nonsense-mediated decay. These same GO terms also appear in the most highly enriched cluster from each of the other three methods, and the corresponding Enrichment Scores from the SFM-SHS, scdNet, and DGCA clusters are 2.95, 2.94, and 2.80, respectively. The DCGs identified by SFM-SHS were also associated with a second enriched cluster. The terms of cytosol, cytoplasm, and phosphoprotein were clustered together with an Enrichment Score of 1.71. All results from DAVID functional annotation clustering tool are provided in the Supplementary Materials.

Lastly, we visualized the differential networks estimated from SFM-SHS and SFM-DHS in **Figures 6**, **7**, respectively. The genegene connections in the figures represent the differential edges for the 7 top DCGs uniquely identified by our methods and the 3 top DCGs identified by all four considered methods. All G = 130 genes are displayed in each figure, but we only display the differential edges for the 10 selected DCGs. Figures of the individual GCNs with these 10 DCGs for the non-hospitalized and hospitalized groups are provided in the **Supplementary Figures S1–S4**.

We see that a majority of these DCGs have differential edges that are a result of larger correlations in the hospitalized group, with *CD200* and *TNFSF8* having the highest numbers of differential edges from this group. *CD200* is a type 1 cell membrane glycoprotein (GP) of the immunoglobulin supergene family that is expressed by many cell types (e.g., B cells, a subset of T cells, endothelial cells, cancer cells). GP plays an important role in immunosuppression and regulation of anti-tumor activity. Moreover, this gene has multiple transcript variances. Naturally, its connectivities are different in the hospitalized group of patients compared to non-hospitalized group.

TNFSF8 is one of the tumor necrosis factor (TNF) receptor superfamily proteins that typically are composed of one to four cysteine-rich domains. It has been suggested that SARS-CoV-2 disease processes present in severe illness contribute to impaired adaptive immune responses. Additionally, TNF super family proteins are most often used in predicting neutralization. Elderly patients severely affected by SARS-CoV-2 have distinctive neutralization activity-associated protein profiles that may display an altered level of *TNFSF8* (Filbin et al., 2021).

Conversely, both *IFI44L* and *XAF1* had the highest number of differential edges as a result of having stronger correlations in the



FIGURE 6 Differential network estimated by SFM-SHS with the bootstrap procedure for the SARS-CoV-2 case study dataset. Edges displayed are for 10 DCGs. The 7 unique top DCGs identified by both SFM-SHS and SFM-DHS are listed in black and the 3 top DCGs identified by all considered methods are listed in green. Each edge color represents the group with the larger correlation magnitude.

non-hospitalized group. Prior studies concluded that SARS-CoV-2 and other viruses elicit an interferon response in the upper airway. Moreover, the most significant genes upregulated by SARS-CoV-2 were interferon inducible, such as *IFI44L* (Butler et al., 2021; Huang et al., 2021). *XAF1* is an X-linked inhibitor of apoptosis (XIAP)-associated factor 1. This gene participates in pro-apoptotic responses and has multiple transcript variants. In Zhu et al. (2020), both *IFI44L* and *XAF1* were upregulated in T, B, natural killer, and DC cell subsets of SARS-CoV-2 patients compared to healthy controls.

4 DISCUSSION

Our proposed model includes continuous treatment-dependent parameters that determine the impact of latent factors for each gene. For simplicity, our methodology has been defined and examined under a two-group situation, but it can be adjusted to a multiple group scenario. In the general case, we can consider *T* number of treatments and represent the $log(\mu_{gi})$ from Eq. 1 in the general form:

$$log(\mu_{gi}) = \beta_g + \sum_{t=1}^{T-1} I(t_i = t) \delta_{g;t} + \sum_{f=1}^{F} \lambda_{if} \alpha_{gf;t_i} - \left\{ \sum_{f=1}^{F} \frac{\alpha_{gf;t_i}^2}{2} \right\}.$$

Here, the $\delta_{g;t}$ parameters depend on the treatment groups $t \in \{1, ..., T-1\}$ and $I(t_i = t)$ is the indicator variable for cell *i* being in treatment group *t*. The construction of gene-gene correlation structures will remain the same, but there will be *T* sets of $\alpha_{gf;t}$ parameters that create *T* different networks to compare. When performing differential network analysis, one can examine the CrIs (or CIs) of the difference between $\rho_{gg';t}$ and $\rho_{gg';t'}$ for each pair of treatments *t* and *t'* ($t \neq t'$).

In addition to identifying differential network edges, our methodology also reports estimates of the GCNs for both the control and treatment group. We found that these estimates generally reflect the "true" underlying correlation structures of



edge color represents the group with the larger correlation magnitude.

the simulated datasets used in **Section 3.1** (see **Supplementary Tables S1, S2**). To the best of our knowledge, the method of scdNet currently does not directly provide the estimations of the control and treatment GCNs, separately.

When applying our methodology, we recommend using an optimization-based procedure for estimating model parameters. Researchers can choose to utilize a single optimization of our model and select the "Top N" genegene correlation differences from the posterior mode or choose to utilize bootstrapping to obtain and analyze the variability of the estimates. Both techniques achieved high AUROCs in the simulation studies, and the bootstrap optimization was able to control the FDRs. Furthermore, bootstrap replicates can be performed in parallel to help reduce computational time. One could choose to utilize a full HMC to obtain parameter estimates and perform model inference, but an iterative MCMC approach may be computationally expensive and will also require the use of diagnostic tools to assess convergence. As an alternative

approach to faster Bayesian computing, we had considered utilizing variational inference as a tool to approximate the posterior distribution and obtain parameter estimates as in Sekula et al. (2019), but our preliminary experiments found that this inference technique did not produce reliable estimates.

When it comes to choosing an appropriate number of factors (*F*) for our methodology, we recommend running different choices for *F* and identifying the "peak" in the number of differential network edges after F = 5 factors (as illustrated in **Figure 3**). Starting with the choice of F = 5 helps to capture the increase in the number of differential edges across increasing values of *F*, and the number of factors associated with the "peak" can be considered the "best" model choice. Generally, we found that F = 7 or F = 8 for the number of factors was a common selection for both SFM-SHS and SFM-DHS in our considered datasets that had between G = 50 to G = 130 genes. Thus, using either F = 7 or F = 8 would be a reasonable default choice for analyses with

similar numbers of genes. For analyses with much larger values of *G*, one may anticipate needing a larger value for *F*.

5 CONCLUSION AND FUTURE SCOPE

In this manuscript, we have presented a sparse hierarchical Bayesian factor model to perform differential network analysis from scRNA-seq count data. With a latent factor structure, we define a count model that is conditionally Poisson but marginally overdispersed, and the flexibility of the defined latent factor structure allows our model to account for other unique features of scRNA-seq data such as zero-inflation and high cell-to-cell variability. Furthermore, the defined horseshoe prior structures in **Eqs. 2–4** promote sparsity in our network estimation and allow information to be shared across treatment groups.

When applying our methodology, our main recommendation is to perform analysis using the SHS version of our model with bootstrapping, as SFM-SHS tends to be better at controlling the FDRs compared to SFM-DHS. We also recommend using some sort of gene selection method (e.g., differential expression) to obtain a manageable number of genes to analyze with our method. Since each GCN is determined by a quadratic number of parameters $\left(\frac{G(G-1)}{2} \text{ correlations}\right)$, it becomes difficult to present results both visually and numerically for larger values of *G*.

As demonstrated in **Section 3.1**, the bootstrapping technique for parameter estimation provides a time-efficient implementation of our methodology that outperforms the competitor methods of scdNet and DGCA. Also, our methods were superior in selecting top DCGs that were

REFERENCES

- Bacher, P., Rosati, E., Esser, D., Martini, G. R., Saggau, C., Schiminsky, E., et al. (2020). Low-avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. *Immunity* 53, 1258–1271. doi:10.1016/j.immuni.2020.11.016
- Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B (Methodological) 57, 289–300. doi:10.1111/j.2517-6161.1995.tb02031.x
- Blencowe, M., Arneson, D., Ding, J., Chen, Y.-W., Saleem, Z., and Yang, X. (2019). Network Modeling of Single-Cell Omics Data: Challenges, Opportunities, and Progresses. *Emerging Top. Life Sci.* 3, 379–398. doi:10.1042/ETLS20180176
- Butler, D., Mozsary, C., Meydan, C., Foox, J., Rosiene, J., Shaiber, A., et al. (2021). Shotgun Transcriptome, Spatial Omics, and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions. *Nat. Commun.* 12, 1660. doi:10.1101/2020.04.20.048066
- Caldana, C., Degenkolbe, T., Cuadros-Inostroza, A., Klie, S., Sulpice, R., Leisse, A., et al. (2011). High-density Kinetic Analysis of the Metabolomic and Transcriptomic Response of Arabidopsis to Eight Environmental Conditions. *Plant J.* 67, 869–884. doi:10.1111/j.1365-313x.2011.04640.x
- Cario, M. C., and Nelson, B. L. (1997). Modeling and Generating Random Vectors with Arbitrary Marginal Distributions and Correlation Matrix. Technical report. Evanston, Illinois: Department of Industrial Engineering and Management Sciences, Northwestern University.
- Carvalho, C. M., Polson, N. G., and Scott, J. G. (2009). "Handling Sparsity via the Horseshoe," in Artificial Intelligence and Statistics. Clearwater Beach, FL: PMLR, 73–80.

associated with biologically enriched clusters of GO categories in **Section 3.2**. Both SFM-SHS and SFM-DHS identified a unique set of top DCGs with biological functions related to the body's response to the SARS-CoV-2 virus. Collectively, these analyses suggest that our sparse Bayesian factor model will be a useful tool for the construction and differential analysis of GCNs in future scRNA-seq experiments. An R package implementing our proposed methodology and code to generate the simulated datasets are available at: https://github.com/mnsekula/scSFMnet.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: https://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE162086.

AUTHOR CONTRIBUTIONS

MS, JG, and SD developed the methodology. MS performed the data analysis and maintains the associated R package. All authors contributed to writing and revising the manuscript and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.810816/full#supplementary-material

- Chan, T. E., Stumpf, M. P. H., and Babtie, A. C. (2017). Gene Regulatory Network Inference from Single-Cell Data Using Multivariate Information Measures. *Cel* Syst. 5, 251–267. doi:10.1016/j.cels.2017.08.014
- Chiu, Y.-C., Hsiao, T.-H., Wang, L.-J., Chen, Y., and Shao, Y.-H. J. (2018). scdNet: A Computational Tool for Single-Cell Differential Network Analysis. *BMC Syst. Biol.* 12, 124. doi:10.1186/s12918-018-0652-0
- Choi, Y., and Kendziorski, C. (2009). Statistical Methods for Gene Set Coexpression Analysis. *Bioinformatics* 25, 2780–2786. doi:10.1093/ bioinformatics/btp502
- Cowles, M. K., and Carlin, B. P. (1996). Markov Chain Monte Carlo Convergence Diagnostics: A Comparative Review. J. Am. Stat. Assoc. 91, 883–904. doi:10.1080/01621459.1996.10476956
- Cui, L., Wang, B., Ren, C., Wang, A., An, H., and Liang, W. (2021). A Novel Method to Identify the Differences between Two Single Cell Groups at Single Gene, Gene Pair, and Gene Module Levels. *Front. Genet.* 12, 297. doi:10.3389/ fgene.2021.648898
- Dai, H., Li, L., Zeng, T., and Chen, L. (2019). Cell-specific Network Constructed by Single-Cell RNA Sequencing Data. *Nucleic Acids Res.* 47, e62. doi:10.1093/nar/ gkz172
- Filbin, M. R., Mehta, A., Schneider, A. M., Kays, K. R., Guess, J. R., Gentili, M., et al. (2021). Longitudinal Proteomic Analysis of Severe COVID-19 Reveals Survival-Associated Signatures, Tissue-specific Cell Death, and Cell-Cell Interactions. *Cel Rep. Med.* 2, 100287. doi:10.1016/ j.xcrm.2021.100287
- Finak, G., McDavid, A., Yajima, M., Deng, J., Gersuk, V., Shalek, A. K., et al. (2015). Mast: A Flexible Statistical Framework for Assessing Transcriptional Changes and Characterizing Heterogeneity in Single-Cell RNA Sequencing Data. *Genome Biol.* 16, 278. doi:10.1186/s13059-015-0844-5

- Fukushima, A. (2013). DiffCorr: An R Package to Analyze and Visualize Differential Correlations in Biological Networks. *Gene* 518, 209–214. doi:10.1016/j.gene.2012.11.028
- Gill, R., Datta, S., and Datta, S. (2010). A Statistical Framework for Differential Network Analysis from Microarray Data. BMC Bioinformatics 11, 95. doi:10.1186/1471-2105-11-95
- Huang, D. W., Sherman, B. T., and Lempicki, R. A. (2009a). Bioinformatics Enrichment Tools: Paths toward the Comprehensive Functional Analysis of Large Gene Lists. *Nucleic Acids Res.* 37, 1–13. doi:10.1093/nar/gkn923
- Huang, D. W., Sherman, B. T., and Lempicki, R. A. (2009b). Systematic and Integrative Analysis of Large Gene Lists Using DAVID Bioinformatics Resources. *Nat. Protoc.* 4, 44–57. doi:10.1038/nprot.2008.211
- Huang, L., Shi, Y., Gong, B., Jiang, L., Zhang, Z., Liu, X., et al. (2021). Dynamic blood single-cell immune responses in patients with COVID-19. Sig. Transduct. Target Ther. 6, 110. doi:10.1038/s41392-021-00526-2
- Huynh-Thu, V. A., Irrthum, A., Wehenkel, L., and Geurts, P. (2010). Inferring Regulatory Networks from Expression Data Using Tree-Based Methods. *PLoS* One 5, e12776. doi:10.1371/journal.pone.0012776
- Langfelder, P., and Horvath, S. (2008). WGCNA: An R Package for Weighted Correlation Network Analysis. BMC Bioinformatics 9, 559. doi:10.1186/1471-2105-9-559
- Lex, A., Gehlenborg, N., Strobelt, H., Vuillemot, R., and Pfister, H. (2014). UpSet: Visualization of Intersecting Sets. *IEEE Trans. Vis. Comput. Graph* 20, 1983–1992. doi:10.1109/TVCG.2014.2346248
- Li, L., Dai, H., Fang, Z., and Chen, L. (2021). c-CSN: Single-Cell RNA Sequencing Data Analysis by Conditional Cell-specific Network. *Genomics, Proteomics & Bioinformatics* 21, 319–329. doi:10.1016/j.gpb.2020.05.005
- Margolin, A. A., Nemenman, I., Basso, K., Wiggins, C., Stolovitzky, G., Favera, R. D., et al. (2006). ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context. BMC Bioinformatics 7, S7. doi:10.1186/1471-2105-7-s1-s7
- Matsumoto, H., Kiryu, H., Furusawa, C., Ko, M. S. H., Ko, S. B. H., Gouda, N., et al. (2017). SCODE: an Efficient Regulatory Network Inference Algorithm from Single-Cell RNA-Seq during Differentiation. *Bioinformatics* 33, 2314–2321. doi:10.1093/bioinformatics/btx194
- McKenzie, A. T., Katsyv, I., Song, W. M., Wang, M., and Zhang, B. (2016). DGCA: a Comprehensive R Package for Differential Gene Correlation Analysis. *BMC Syst. Biol.* 10, 106–125. doi:10.1186/s12918-016-0349-1
- Neal, R. M. (2011). "MCMC Using Hamiltonian Dynamics," in Handbook of Markov Chain Monte Carlo. Boca Raton, FL: CRC Press 2, 2. doi:10.1201/ b10905-6
- R Core Team (2018). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: https:// www.R-project.org/.
- Rofeal, M., and El-Malek, F. A. (2020). Ribosomal Proteins as a Possible Tool for Blocking SARS-COV 2 Virus Replication for a Potential Prospective Treatment. *Med. Hypotheses* 143, 109904. doi:10.1016/j.mehy.2020.109904
- Sekula, M., Gaskins, J., and Datta, S. (2020). A Sparse Bayesian Factor Model for the Construction of Gene Co-expression Networks from Single-Cell RNA Sequencing Count Data. *BMC Bioinformatics* 21, 361. doi:10.1186/s12859-020-03707-y
- Sekula, M., Gaskins, J., and Datta, S. (2019). Detection of Differentially Expressed Genes in Discrete Single-cell RNA Sequencing Data Using a

Hurdle Model with Correlated Random Effects. *Biometrics* 75, 1051-1062. doi:10.1111/biom.13074

- Specht, A. T., and Li, J. (2016). LEAP: Constructing Gene Co-expression Networks for Single-Cell RNA-Sequencing Data Using Pseudotime Ordering. *Bioinformatics* 33, 764–766. doi:10.1093/bioinformatics/btw729
- Stan Development Team (2020). *RStan: The R Interface to Stan*. R Package version 2.21.2. Available at: http://mc-stan.org (Accessed October 28, 2021).
- Tay, T. L., Sagar, J., Dautzenberg, J., Grün, D., and Prinz, M. (2018). Unique Microglia Recovery Population Revealed by Single-Cell RNAseq Following Neurodegeneration. *Acta Neuropathol. Commun.* 6, 87. doi:10.1186/s40478-018-0584-3
- Tesson, B. M., Breitling, R., and Jansen, R. C. (2010). DiffCoEx: A Simple and Sensitive Method to Find Differentially Coexpressed Gene Modules. BMC Bioinformatics 11, 497–499. doi:10.1186/1471-2105-11-497
- Touloumis, A. (2016). Simulating Correlated Binary and Multinomial Responses under Marginal Model Specification: The SimCorMultRes Package. R. J. 8, 79. doi:10.32614/rj-2016-034
- Wang, Y., Wu, H., and Yu, T. (2017). Differential Gene Network Analysis from Single Cell RNA-Seq. J. Genet. Genomics 44, 331–334. doi:10.1016/ j.jgg.2017.03.001
- Weston, D. J., Karve, A. A., Gunter, L. E., Jawdy, S. S., Yang, X., Allen, S. M., et al. (2011). Comparative Physiology and Transcriptional Networks Underlying the Heat Shock Response in Populus trichocarpa, *Arabidopsis thaliana* and Glycine max. *Plant Cel Environ.* 34, 1488–1506. doi:10.1111/j.1365-3040.2011.02347.x
- Yang, M., Zamba, G., and Cavanaugh, J. (2018). ZIM: Zero-Inflated Models (ZIM) for Count Time Series with Excess Zeros. R Package Version 1.1.0. Available at: https://CRAN.R-project.org/package=ZIM (Accessed July 31, 2021).
- Ye, X., Zhang, W., Futamura, Y., and Sakurai, T. (2020). Detecting Interactive Gene Groups for Single-Cell RNA-Seq Data Based on Co-expression Network Analysis and Subgraph Learning. *Cells* 9, 1938. doi:10.3390/cells9091938
- Zhu, L., Yang, P., Zhao, Y., Zhuang, Z., Wang, Z., Song, R., et al. (2020). Single-cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients. *Immunity* 53, 685–696. doi:10.1016/j.immuni.2020.07.009

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Sekula, Gaskins and Datta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.